{"id":"NCT00711880","sponsor":"Jazz Pharmaceuticals","briefTitle":"A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.","officialTitle":"A Double Blind, Randomised, Placebo Controlled Parallel Group Study of Cannabis Based Medicine Extract (CBME), in the Treatment of Peripheral Neuropathic Pain Characterised by Allodynia.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-05","primaryCompletion":"2004-03","completion":"2004-03","firstPosted":"2008-07-09","resultsPosted":"2012-09-28","lastUpdate":"2023-04-12"},"enrollment":125,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"SUPPORTIVE_CARE"},"conditions":["Pain","Peripheral Neuropathy"],"interventions":[{"type":"DRUG","name":"Sativex®","otherNames":["GW-1000-02"]},{"type":"DRUG","name":"Placebo","otherNames":["GW-4001-01"]}],"arms":[{"label":"Sativex","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy of Sativex® compared with placebo in relieving peripheral neuropathic pain associated with allodynia.","primaryOutcome":{"measure":"Change From Baseline in the Mean Daily Peripheral Neuropathic Pain on a 0-10 Numerical Rating Scale Score During the Last Seven Days of Treatment (End of Treatment)","timeFrame":"Day 0 to Day 42","effectByArm":[{"arm":"Sativex","deltaMin":-1.57,"sd":2.11},{"arm":"Placebo","deltaMin":-0.59,"sd":1.38}],"pValues":[{"comp":"OG000 vs OG001","p":"0.004"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":18},"locations":{"siteCount":1,"countries":["United Kingdom"]},"refs":{"pmids":["17997224"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":63},"commonTop":["Dizziness","Nausea","Fatigue","Headache NOS","Dry Mouth"]}}